RxDoctor Payments Data

Daris Hackward, PA

Physician Assistant · Olathe, KSNPI 1235690546

Payments from drug & device makers

$2,095in general payments, 2019–2025

Across 90 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$621
  • AbbVie$509
  • Urovant Sciences Inc$193
  • Endo Pharmaceuticals Inc.$116
  • Sumitomo Pharma America, Inc.$109
  • Urogen Pharma, Inc.$88
  • plus $460 from 15 others

What the payments were for

  • Travel & lodging$60629%
  • Food & beverage$1,48971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,095 in reported general payments places this provider in the 80th percentile of 1,016 physician assistant providers in Kansas.

See all physician assistant providers in Kansas

Medicare billing

Part B allowed, 2024
$46,964
Medicare patients
294
Services billed
1,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron65$47,608
MyrbetriqMirabegron17$18,197
Potassium Citrate ErPotassium Citrate37$2,607
Estradiol41$2,209
Tamsulosin Hcl151$1,989
Trospium Chloride ErTrospium Chloride13$1,362
Methenamine Hippurate20$1,306
Lidocaine Hcl13$1,145
Trospium Chloride12$685
Finasteride68$602
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst34$469
Cephalexin41$363
Testosterone Cypionate13$348
Oxybutynin Chloride ErOxybutynin Chloride16$157
Sodium ChlorideSodium Chloride Irrig Solution11$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$109$47,60865 claims
Astellas Pharma US IncMyrbetriq$60$18,19717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,016 physician assistant providers in Kansas.

Other physician assistant in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →